QXL-138AM

N/A

Report date: 2025/06/12 20:00:09

Base Information

Drug NameQXL-138AM
Drug Alias NameQXL-138AM
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD138Interferon alpha/beta receptor agonistsWnt signalling pathway inhibitors
TargetsSyndecan-1Interferon alpha/beta receptor
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNammi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMyeloma Investment FundNammi Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsLung Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A